PALO ALTO, Calif. (AP) _ Eiger BioPharmaceuticals Inc. (EIGR) on Thursday reported a loss of $17.2 million in its first quarter.
The Palo Alto, California-based company said it had a loss of 90 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 88 cents per share.
Eiger BioPharma shares have risen nearly 8% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.94, a climb of 11% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EIGR at https://www.zacks.com/ap/EIGR